The dengue virus non-structural 1 protein: Risks and benefits

Virus Research

Volumn 181, Issue , 2014, Pages 53-60

  Amorim, Jaime Henrique ^a   Alves, Rúbens Prince dos Santos ^a   Boscardin, Silvia Beatriz ^a   Ferreira, Luís Carlos de Souza ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antiviral; Dengue virus; Diagnosis; NS1 protein; Pathogenesis; Vaccine

Indexed keywords

ANTIVIRAL; DENGUE VIRUS; DIAGNOSIS; NS1 PROTEIN; PATHOGENESIS; VACCINE;

ANIMALS; ANTIVIRAL AGENTS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HUMANS; LIFE CYCLE STAGES; PUBLIC HEALTH; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84893821040     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2014.01.001     Document Type: Review

References (77)

1. Alcon S., Talarmin A., Debruyne M., Falconar A., Deubel V., Flamand M. Enzyme-linked immunosorbent assay specific to dengue virus Type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. J. Clin. Microbiol. 2002, 40:376-381.
2. Amorim J.H., Bizerra R.S.P., Alves R.P.S., Sbrogio-Almeida M.E., Levi J.E., Capurro M.L., Ferreira L.C.S. A genetic and pathologic study of a DENV2 clinical isolate capable of inducing hemorrhage and encephalitis in immunocompetent mice. Plos One 2012, 7:e44984.
3. Amorim J.H., Diniz M.O., Cariri F.A., Rodrigues J.F., Bizerra R.S., Gonçalves A.J.S., Alves A.M.B., Ferreira L.C.S. Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant. Vaccine 2012, 5:837-845.
4. Avirutnan P., Zhang L., Punyadee N., Manuyakorn A., Puttikhunt C., Kasinrerk W., Malasit P., Atkinson J.P., Diamond M.S. Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. PLoS Pathogens 2007, 3:e183.
5. Avirutnan P., Fuchs A., Hauhart R.E., Somnuke P., Youn S., Diamond M.S., Atkinson J.P. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J. Exp. Med. 2010, 207:793-806.
6. Avirutnan P., Hauhart R.E., Somnuke P., Blom A.M., Diamond M.S., Atkinson J.P. Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. J. Immunol. 2011, 187:424-433.
7. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., Drake J.M., Brownstein J.S., Hoen A.G., Sankoh O., Myers M.F., George D.B., Jaenisch T., Wint G.R., Simmons C.P., Scott T.W., Farrar J.J., Hay S.I. The global distribution and burden of dengue. Nature 2013, 7446:504-507.
8. Blacksell S.D., Richard G.J., Robert V.G., Ampai T., Mammen M.P., Nisalak A., Kalayanarooj S., Bailey M.S., Premaratna R., de Silva H.J., Dayand N.P.J., Lalloo D.G. Comparison of Seven commercial antigen and antibody enzyme-linked immunosorbent assays for detection of acute dengue infection. Clin. Vacc. Immunol. 2012, 19:804-810.
9. Chaiyaratana W., Chuansumrit A., Pongthanapisith V., Tangnararatchakit K., Lertwongrath S., Yoksan S. Evaluation of dengue nonstructural protein 1 antigen strip for the rapid diagnosis of patients with dengue infection. Diagn. Microbiol. Infect. Dis. 2009, 64:83-84.
10. Chaterji S., Allen J.C., Chow A., Leo Y-S., Ooi E-E. Evaluation of the NS1 Rapid Test and the WHO dengue classification schemes for use as bedside diagnosis of acute dengue fever in adults. Am. J. Trop. Med. Hyg. 2011, 84:224-228.
11. Chen M.C., Lin C.F., Lei H.Y., Lin S.C., Liu H.S., Yeh T.M., Anderson R., Lin Y.S. Deletion ofthe Cterminal region of dengue virus nonstructuralprotein 1 (NS1) abolishes antiNS1mediated platelet dysfunction and bleeding tendency. J. Immunol. 2009, 183:1797-1803.
12. Cheng H.J., Lei H.Y., Lin C.F., Luo Y.H., Wan S.W., Liu H.S., Yeh T.M., Lin Y.S. Anti-dengue virus nonstructural protein 1 antibodies recognize protein disulfide isomerase on platelets and inhibit platelet aggregation. Mol. Immunol. 2009, 47:398-406.
13. Costa S.M., Paes M.V., Barreto D.F., Pinhão A.T., Barth O.M., Queiroz J.L.S., Armôa G.R.G., Freire M.S., Alves A.M.B. Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence. Vaccine 2006, 24:195-205.
14. Costa S.M., Azevedo A.S., Paes M.V., Sarges F.S., Freire M.S., Alves A.M.B. DNA vaccines against dengue virus based on the ns1 gene: The influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice. Virology 2007, 358:413-423.
15. den Haan J.M., Lehar S.M., Bevan M.J. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 2000, 192:1685-1696.
16. den Haan J.M., Bevan M.J. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J. Exp. Med. 2002, 196:817-827.
17. Dussart P., Petit L., Labeau B., Bremand L., Leduc A., Moua D., Matheus S., Baril L. Evaluation of two new commercial tests for the diagnosis of acute dengue virus infection using NS1 antigen detection in human serum. PLoS Neglect. Trop. Dis. 2008, 2:e280.
18. Falconar A.K.I. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Arch. Virol. 1997, 142:897-916.
19. Falconar A.K.I. Antibody responses are generated to immunodominant ELK/KLEtype motifs onthe nonstructural1glycoprotein during live dengue virus infections in mice and humans: implications for diagnosis,pathogenesis,and vaccine design. Clin. Vaccine Immunol. 2007, 14:493-504.
20. Falconar A.K., Martinez F. The NS1 glycoprotein can generate dramatic antibody enhanced dengue viral replication in normal out bred mice resulting in lethal multi-organ disease. PLoS One 2011, 6:e21024.
21. Falgout B., Chanock R., Lai C-J. Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a. J. Virol. 1989, 63:1852-1860.
22. Falgout B., Bray M., Schlesinger J.J., Lai C.J. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J. Virol. 1990, 64:4356-4363.
23. Falgout B., Markoff L. Evidence that flavivirus NS1-NS2A cleavage is mediated by a membrane-bound host protease in the endo-plasmic reticulum. J. Virol. 1995, 69:7232-7243.
24. Flamand M., Megret F., Mathieu M., Lepault J., Rey F.A., Deubel V. Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion. J. Virol. 1999, 70:6104-6110.
25. Fry S.R., Meyer M., Semple M.G., Simmons C.P., Sekaran S.D., Huang J.X., McElnea C., Huang C.Y., Valks A., Young P.R., Cooper M.A. The diagnostic sensitivity of dengue rapid test assays is significantly enhanced by using a combined antigen and antibody testing approach. PLoS Neglect. Trop. Dis. 2011, 5:e1199.
26. Groen J., Koraka P., Velzing J., Copra C., Osterhaus A.D. Evaluation of six immunoassays for detection of dengue virus-specific immunoglobulin M and G antibodies. Clin. Diagn. Lab. Immunol. 2000, 7:867-871.
27. Gubler D.J. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 1998, 11:480-496.
28. Gubler D.J., Meltzer M. Impact of dengue/dengue hemorrhagic fever on the developing world. Adv. Virus Res. 1999, 53:35-70.
29. Guzman M.G., Halstead S.B., Artsob H., Buchy P., Farrar J., Gubler D.J., Hunsperger E., Kroeger A., Harold S.M., Martinez E., Nathan M.B., Pelegrino J.L., Simmons C., Yoksan S., Peeling R.W. Dengue: a continuing global threat. Nat. Rev. Microbiol. 2010, S7-S16.
30. Halstead S.B. Dengue. Lancet 2007, 370:1644-1652.
31. Hang V.T., Nguyet N.M., Trung D.T., Tricou V., Yoksan S., Dung N.M., Van N.T., Hien T.T., Farrar J., Wills B., Simmons C.P. Diagnostic accuracy of NS1 ELISA and lateral flow rapid tests for dengue sensitivity, specificity and relationship to viraemia and antibody responses. PLoS Neglect. Trop. Dis. 2009, 3:e360.
32. Henchal E.A., Henchal L.S., Schlesinge r.J.J. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J. Gen. Virol. 1988, 69:2101-2107.
33. Henriques H.R., Rampazo E.V., Gonçalves A.J., Vicentin E.C., Amorim J.H., Panatieri R.H., Amorim K.N., Yamamoto M.M., Ferreira L.C., Alves A.M., Boscardin S.B. Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge. PLoS Neglected Trop. Dis. 2013, 18:e2330. http://www.cdc.gov/ncidod/dvbid/arbor/arbdet.htm accessed in 03.09.2012.
34. Huang S.S., Li I.H., Hong P.D., Yeh M.K. Evaluation of protective efficacy using a nonstructural protein NS1 in DNA vaccine-loaded microspheres against dengue 2 virus. Int. J. Nanomed. 2013, 8:3161-3169.
35. Kalluri S., Gilruth P., Rogers D., Szczur M. Surveillance of arthropod vector-borne infectious diseases using remote sensing techniques: a review. PLoS Pathogens 2007, 10:1361-1371.
36. Koraka P., Zeller H.G., Niedrig M., Osterhaus A., Groen J. Reactivity of serum samples from patients with flavivirus infections measured with immunofluorescence assay and ELISA. Microb. Infect. 2002, 4:1209-1215.
37. Kurosu T., Chaichana P., Yamate M., Anantapreecha S., Ikuta K. Secreted complement regulatory protein clusterin interacts with dengue virus nonstructural protein 1. Biochem. Biophys. Res. Commun. 2007, 362:1051-1056.
38. Lanciotti R.S., Calisher C.H., Gubler D.J., Chang G.J., Vorndam A.V. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J. Clin. Microbiol. 1992, 30:545-551.
39. Lemes E.M., Miagostovicsh M.P., Alves A.M., Costa S.M., Fillipis A.M., Armoa G.R., Araujo M.A. Circulating human antibodies against dengue NS1 protein: potential of recombinant D2V-NS1 proteins in diagnostic tests. J. Clin. Virol. 2005, 32:305-312.
40. Lin C.F., Lei H.Y., Liu C.C., Liu H.S., Yeh T.M., Wang S.T., Yang T.I., Sheu F.C., Kuo C.F., Lin Y.S. Generation of IgM anti-platelet autoantibody in dengue patients. J. Med. Virol. 2001, 63:143-149.
41. Lin H-F., Lei H-Y., Shiau A-L., Liu H-S., Yeh T-M., Chen S-H., Liu C-C., Chiu S-C., Lin Y-S. Endothelial cell apoptosis induced by antibodies against dengue virus nonstructural protein 1 via production of nitric oxide. J. Immunol. 2002, 169:657-664.
42. Lin C.F., Lei H.Y., Shiau A.L., Liu C.C., Liu H.S., Yeh T.M., Chen S.H., Lin Y.S. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. J. Med. Virol. 2003, 69:82-90.
43. Lin C-F., Wan S-W., Cheng H-J., Lei H-Y., Lin Y-S. Autoimmune pathogenesis in dengue virus infection. Viral Immunol. 2006, 19:127-132.
44. Lin S.W., Chuang Y.C., Lin Y.S., Lei H.Y., Liu H.S., Yeh T.M. Dengue virus nonstructural protein NS1 binds to prothrombin/thrombin and inhibits prothrombin activation. J. Infect. 2012, 64:325-334.
45. Lindenbach B.D., Rice C.M. trans-Complementation of yellow fever virus NS1 reveals a role in early RNA replication. J. Virol. 1997, 71:9608-9617.
46. Lindenbach B.D., Rice C.M. Flaviviridae: the viruses and their replication. Fields Virology 2001, 991-1041. Lippincott Williams and Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
47. Mackenzie J.M., Jones M.K., Young P.R. Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication. Virology 1996, 220:232-240.
48. Martina B.E.E., Koraka P., Osterhaus A.D.M.E. Dengue virus pathogenesis: an integrated view. Clin. Microbiol. Rev. 2009, 22:564-581.
49. Mohan S., McAtamney S., Jayakanthan K., Eskandari R., von Itzstein M., Pinto B.M. Antiviral activities of sulfonium-ion glucosidase inhibitors and 5-thiomannosylamine disaccharide derivatives against dengue virus. Int. J. Antimicrob. Agents 2012, 40:273-276.
50. Muller D.A., Corrie S.R., Coffey J., Young P.R., Kendall M.A. Surface modified microprojection arrays for the selective extraction of the dengue virus NS1 protein as a marker for disease. Anal. Chem. 2012, 84:3262-3268.
51. Muller D.A., Young P.R. The flavivirus NS1 protein: molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker. Antiviral Res. 2013, 98:192-208.
52. Muylaert I.R., Galler R.G., Rice C.M. Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence. Virology 1996, 222:159-168.
53. PAHO, 1994. Dengue and Dengue Hemorrhagic Fever in the Americas: Guidelines for Prevention and Control 1994. Pan American Health Organization, Washington, DC, USA.
54. Pongsumpun P., Garcia-Lopez D., Favier C., Torres L., Llosa J., Dubois M.A. Dynamics of dengue epidemics in urban contexts. Trop. Med. Internal Health 2008, 9:1180-1187.
55. Pooley J.L., Heath W.R., Shortman K. Cutting edge: intravenous soluble antigen is presented to CD4T cells by CD8- dendritic cells, but cross-presented to CD8T cells by CD8+ dendritic cells. J. Immunol. 2001, 166:5327-5330.
56. Pryor M.J., Wright P.J. Glycosylation mutants of dengue virus NS1 protein. J. Gen. Virol. 1994, 75:1183-1187.
57. Qu X., Chen W., Maguire T., Austin F. Immunoreactivity and protective effects in mice of a recombinant dengue 2 Tonga virus NS1 protein produced in a baculovirus expression system. J. Gen. Virol. 1993, 74:89-97.
58. Rajapakse S. Dengue Shock. J. Emerg. Trauma Shock 2011, 4:120-127.
59. Ramirez A.H., Moros Z., Comach G., Zambrano J., Bravo L., Pinto B., Vielma S., Cardier J., Liprandi F. Evaluation of dengue NS1 antigen detection tests with acute sera from patients infected with dengue virus in Venezuela. Diagn. Microbiol. Infect. Dis. 2009, 65:247-253.
60. Rathore A.P., Paradkar P.N., Watanabe S., Tan K.H., Sung C., Connolly J.E., Low J., Ooi E.E., Vasudevan S.G. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res. 2011, 92:453-460.
61. Sampath A., Padmanabhan R. Molecular targets for fl{ligature}avivirus drug discovery. Antiviral Res. 2008, 81:6-15.
62. Schlesinger J.J., Brandriss M.W., Walsh E.E. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J. Gen. Virol. 1987, 68:853-857.
63. Srivastava A.K., Putnak J.R., Warren R.L., Hoke C.H. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 1995, 13:1251-1258.
64. TDR/WHO, 2009. In Dengue Guidelines for Diagnosis, Treatment, Prevention and Control. 23-55 (TDR/WHO, Geneva, Switzerland).
65. Vazquez S., Ruiz D., Barrero R., Ramirez R., Calzada N., del Rosario Pena B., Reyes S., Guzman M.G. Kinetics of dengue virus NS1 protein in dengue 4-confirmed adult patients. Diagn. Microbiol. Infect. Dis. 2010, 68:46-49.
66. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., Rothman A.L., Ennis F.A., Nisalak A. Dengue in the early febrile phase: viremia and antibody responses. J. Infect. Dis. 1997, 76:322-330.
67. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., Endy T.P., Raengsakulrach B., Rothman A.L., Ennis F.A., Nisalak A. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 2000, 181:2-9.
68. Watanabe S., Rathore A.P., Sung C., Lu F., Khoo Y.M., Connolly J., Low J., Ooi E.E., Lee H.S., Vasudevan S.G. Dose and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res. 2012, 96:32-35.
69. Whitby K., Pierson T.C., Geiss B., Lane K., Engle M., Zhou Y., Doms R.W., Diamond M.S. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J. Virol. 2005, 79:8698-8706.
70. Whitehead S.S., Blaney J.E., Durbin A.P., Murphy B.R. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 2007, 7:518-528.
71. Winkler G., Randolph V.B., Cleaves G.R., Ryan T.E., Stollar V. Evidence that the mature form of the flavivirus nonstructural protein NS1 is a dimer. Virology 1988, 1:187-196.
72. WHO, 1997. Dengue haemorrhagic fever: diagnosis, treatment prevention and control (WHO, Geneva, Switzerland).
73. Wu S-F., Liao C-L., Lin Y-L., Yeh C-T., Chen L-K., Huang Y-F., Chou H-Y., Huang J-L., Shaio M-F., Sytwu H-K. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 2003, 21:3919-3929.
74. Young P.R., Hilditch P.A., Bletchly C., Halloran W. An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. J. Clin. Microbiol. 2000, 38:1053-1057.
75. Zainah S., Wahab A.H., Mariam M., Fauziah M.K., Khairul A.H., Roslina I., Sairulakhma A., Kadimon S.S., Jais M.S., Chua K.B. Performance of a commercial rapid dengue NS1 antigen immunochromato-graphy test with reference to dengue NS1 antigen-capture ELISA. J. Virol. Methods 2009, 155:157-160.
76. Zhang Y.M., Hayes E.P., McCarty T.C., Dubois D.R., Summers P.L., Eckels K.H., Chanock R.M., Lai C.J. Immunization of mice with dengue structural protein and nonstructural protein NS1 expressed by baculovirus recombinant induces resistance to dengue virus encephalitis. J. Virol. 1988, 62:3027-3031.
77. Zhou J.M., Tang Y.X., Fang D.Y., Zhou J.J., Liang Y., Guo H.Y., Jiang L.F. Secreted expression and purification of dengue 2 virus full-length nonstructural glycoprotein NS1 in Pichia pastoris. Virus Genes 2006, 33:27-32.